Imatron, a manufacturer of ultra-high-speed CT systems, reported that sales jumped by 34% and the companyreturned to profitability in 1994 (ending Dec. 31). Revenues last year totaled a record $33.5 million, comparedto $25.1 million in 1993. Profits
Imatron, a manufacturer of ultra-high-speed CT systems, reported that sales jumped by 34% and the companyreturned to profitability in 1994 (ending Dec. 31).
Revenues last year totaled a record $33.5 million, comparedto $25.1 million in 1993. Profits were $2.3 million.
The financial good news is a continuation of positive trendsthat emerged in the second half of 1993, according to S. LewisMeyer, chief executive officer.
"The company moves into 1995 with a strong backlog anda high degree of optimism in our ability to continue growing,"he said.
Imatron is gearing up sales and marketing efforts in the PacificRim, Latin America and the Middle East. The launch of HeartScan,a subsidiary that will manage artery disease risk assessment centersequipped with Imatron high-speed CT scanners, is scheduled forthe first quarter of 1995, Meyer said.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.